Prithviraj Bose, MD

Dr. Bose is Associate Professor in the Department of Leukemia at the MD Anderson Cancer Center in Houston.

Articles by Prithviraj Bose, MD

Prithviraj Bose, MDMeeting News | December 30, 2024
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Prithviraj Bose, MDMeeting News | December 30, 2024
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
Esteemed experts provide valuable insights into the evolving myelofibrosis landscape and its implications for patient care.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
Key takeaways from the top ASH abstracts in the myelofbrosis space.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
A roundtale discussion starts with a conversation about the myelofibrosis treatment landscape.
Prithviraj Bose, MDMyelofibrosis | September 25, 2024
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | September 17, 2024
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Melissa BadamoMyelofibrosis | July 24, 2024
New therapies, such as TP-3654, are currently being explored in combination studies.
Prithviraj Bose, MDMyelofibrosis | May 2, 2024
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
Prithviraj Bose, MDMyelofibrosis | September 5, 2023
Prithviraj Bose, MD, and colleagues presented results of the study during the 2023 ASCO Annual Meeting.
Cecilia BrownMyelofibrosis | September 5, 2023
Pacritinib demonstrates consistent efficacy for spleen and symptom response in patients with MF regardless of blood counts.
Helen T. Chifotides, PhDMyelofibrosis | January 21, 2022
Experts discuss emerging therapeutic targets, the impact of recently approved agents, and incorporating them into practice.